HIPAA §164.508 compliance is one of the most operationally consequential frameworks in life settlement transactions. Unlike treatment, payment, or healthcare operations (TPO) disclosures where covered entities may share PHI without express authorization, life settlement transactions involve PHI disclosure to third parties (life expectancy underwriting firms, buy-side counterparties, servicer administrators) that requires explicit written authorization. The framework operates as consumer protection for the insured and as compliance defense for every party in the disclosure chain. After more than two decades coordinating buy-side HIPAA workflows across hundreds of transactions, the framework below organizes the operational discipline that supports institutional-grade compliance.

HIPAA §164.508 framework for life settlement disclosure

The HIPAA Privacy Rule generally permits covered entities (healthcare providers, health plans, healthcare clearinghouses) to use or disclose protected health information (PHI) for treatment, payment, or healthcare operations (TPO) purposes without patient authorization. For disclosures outside TPO — including all disclosures to third parties for purposes unrelated to the individual's healthcare — the covered entity must obtain a valid written authorization under 45 CFR §164.508 before releasing the PHI.

Life settlement transactions fall squarely into the authorization-required category. The medical records that flow through a life settlement transaction serve one primary purpose: LE (life expectancy) underwriting to assess the insured's expected mortality timing for pricing and portfolio construction. This is not TPO — it is disclosure to third parties for purposes unrelated to the insured's healthcare. Every party in the disclosure chain (broker, provider, LE underwriting firm, buy-side acquirer, servicer) must operate under a valid HIPAA authorization for the specific PHI they receive.

Under §164.508(a), a covered entity may not use or disclose PHI without a valid authorization. Under §164.508(b), a valid authorization must meet specific requirements including the core elements and required statements below. Under §164.508(b)(5), the individual may revoke the authorization in writing at any time, subject to two exceptions: (1) if the covered entity has already taken action in reliance on the authorization, or (2) if the authorization was obtained as a condition of obtaining insurance coverage and other law provides the insurer with the right to contest a claim under the policy.

The reliance exception is particularly important for life settlement transactions. Once the acquirer has completed the transaction based on medical records obtained under valid authorization, the acquirer's reliance is established — subsequent revocation of the authorization does not unwind the completed transaction. This operational stability is essential for buy-side counterparties. However, ongoing PHI disclosures (subsequent LE re-underwriting during holding period, ongoing servicer administration) may require refreshed authorization if the original expired or was revoked.

6 core elements + 3 required statements

A valid HIPAA authorization must contain the six core elements under §164.508(c)(1) and the three required statements under §164.508(c)(2). The framework below organizes each element and statement with life settlement operational application.

The authorization must be written in plain language and provide the insured with a copy of the signed document. Covered entities must document and retain any signed authorization consistent with §164.530(j) recordkeeping requirements — generally six years from the date of creation or the date the authorization was last in effect, whichever is later. For institutional buy-side life settlement investments, documentation retention typically extends to seven years or longer to align with tax reporting record retention standards.

4-node disclosure chain from insured to investor

Life settlement PHI disclosure operates through a 4-node chain of custody with progressively narrower PHI scope at each node. Understanding the chain is essential for both authorization drafting (identifying appropriate class of recipients) and downstream privacy protection framework (contractual obligations where HIPAA no longer applies).

Two operational observations about the disclosure chain deserve emphasis. First, PHI scope progressively narrows. Nodes 01-03 receive full medical records for mortality assessment; Node 04 (investor) typically receives only redacted LE report conclusions rather than raw underlying medical records. This principle of minimum necessary disclosure aligns with HIPAA's operational preference and institutional privacy best practice. Second, HIPAA coverage weakens downstream. Node 01 (healthcare providers) are covered entities under HIPAA. Nodes 02-04 (provider/broker, LE underwriter, investor) are typically not covered entities themselves. Downstream privacy protection depends on contractual obligations (data processing agreements, business associate agreements where applicable, standard confidentiality provisions) rather than direct HIPAA coverage.

12-month renewal protocol and revocation handling

HIPAA authorizations for life settlement transactions typically operate under 12-24 month expiration periods per the standard operational framework. This creates two operational realities that disciplined buy-side coordination must address: renewal for ongoing disclosures and handling revocation notices.

Renewal protocol. If ongoing PHI access remains necessary during the multi-year holding period (for periodic LE re-underwriting, ongoing servicer administration, or portfolio-level portfolio review), the authorization must be refreshed before expiration. Standard institutional practice includes 60-90 day advance renewal notifications with refreshed authorization forms sent to the insured or their personal representative.

Revocation handling. Under §164.508(b)(5), the insured may revoke the authorization in writing at any time. Two exceptions preserve completed transactions: (1) the reliance exception protecting actions already taken based on the authorization, and (2) the insurance coverage exception where other law provides right to contest a claim. In life settlement context, the reliance exception typically protects the completed acquisition transaction — the transaction cannot be unwound by subsequent revocation. However, ongoing PHI disclosure obligations (for re-underwriting, servicer administration) may be affected by revocation.

• Documentation of revocation notice receipt. The revocation is effective when received in writing by the covered entity. Documentation of exact receipt date supports compliance timing analysis.
• Immediate cessation of ongoing disclosures. Upon receipt of revocation notice, further disclosures based on the revoked authorization must cease immediately. Prior disclosures already in progress may be completed under the reliance exception.
• Coordination with downstream nodes. The provider or LE underwriter receiving PHI must be notified of the revocation so ongoing use of already-received PHI can be evaluated. The reliance exception generally protects use of PHI already provided; new disclosures cease.
• Alternative authorization pathways. If ongoing PHI access remains operationally necessary, alternative authorization pathways (freshly executed authorization with updated scope) may be pursued through the insured's cooperation.
• Documentation retention. Both the original authorization and any revocation notices must be retained under §164.530(j) recordkeeping requirements — generally six years minimum, seven years or longer for institutional buy-side compliance alignment with tax reporting standards.

For accredited investors evaluating life settlement investments, disciplined HIPAA workflow at the provider/broker level is a diligence element worth evaluating. Opportunities where the provider counterparty demonstrates institutional-grade HIPAA framework represent lower operational risk than counterparties with unclear authorization protocols.

Special PHI sensitivities — Part 2, HIV, mental health

Certain categories of PHI carry additional federal or state law protections beyond baseline HIPAA framework. Disciplined life settlement HIPAA workflows must address these enhanced protections where applicable to the insured's medical history.

• Substance use disorder records under 42 CFR Part 2. Federally-supported substance use disorder treatment records are protected under separate framework requiring more specific consent than baseline HIPAA authorization. Life settlement authorization may need supplementary 42 CFR Part 2 consent if the insured's medical history includes substance use disorder treatment.
• HIV/AIDS status under state law. Many states impose additional consent requirements for HIV/AIDS status disclosure beyond HIPAA baseline. Authorization language should address state-specific HIV consent requirements where the insured resides in states with enhanced protections.
• Mental health records. While psychotherapy notes (separate confidential notes maintained by the mental health provider) carry heightened HIPAA protection, general mental health treatment records typically follow standard HIPAA framework. Some states impose additional mental health record protections.
• Genetic information under GINA. The Genetic Information Nondiscrimination Act imposes additional restrictions on genetic information use. While GINA primarily targets employment and health insurance, the framework may affect life settlement transaction structuring.
• State-specific PHI variations. California (CMIA), New York, and other states impose additional PHI protections beyond HIPAA baseline. Authorization framework should address state law variations where the insured resides in high-protection states.

The enhanced protections generally require additional or more specific consent language rather than blocking disclosure entirely. Institutional-grade authorization framework typically includes standardized language addressing the most common enhanced protection categories with case-specific supplementation where the insured's medical history triggers specific enhanced requirements.

Frequently asked questions

Disclaimer — This content is for educational and informational purposes only and does not constitute legal, regulatory, financial, tax, healthcare, privacy, or investment advice. The HIPAA §164.508 authorization framework discussion (6 core elements, 3 required statements, revocation protocol) reflects 45 CFR §164.508 as revised through publication date; specific application to any particular transaction requires qualified privacy counsel review under current HHS Office for Civil Rights guidance. The 4-node disclosure chain framework (Insured/Provider → Provider/Broker → LE Underwriter → Investor) reflects general institutional structure; specific transactions may involve additional nodes (e.g., third-party administrators, portfolio-level servicers, secondary market intermediaries) not discussed. The 12-24 month expiration period discussion reflects standard operational practice; individual authorizations may use different expiration structures. The reliance exception under §164.508(b)(5)(i) discussion reflects general legal interpretation; specific application in individual transactions requires qualified counsel analysis. Special PHI sensitivities discussion (42 CFR Part 2 substance use disorder, HIV/AIDS state protections, mental health records, GINA genetic information, CMIA and other state-specific frameworks) is illustrative rather than exhaustive; specific enhanced protections may apply to individual medical histories not addressed in the general framework. State law variations from HIPAA baseline vary materially across the 50 states; specific state analysis requires qualified counsel review. References to specific LE underwriting firms (21st Services, ISC Services, Fasano Associates, Predictive Resources) reflect industry-standard practice rather than endorsement or business relationship. Documentation retention discussion (6 year minimum under §164.530(j), 7+ years institutional practice) reflects general framework; specific retention obligations may vary by circumstance. Life settlement investments are illiquid, long-duration alternative assets and are generally available only to accredited investors as defined under SEC Rule 501 of Regulation D. Investments involve substantial risk, including potential loss of capital. High Yield Vault is a life settlement investment platform that originates, researches, and presents direct-ownership investment opportunities to accredited investors. HYV is not a healthcare provider, not a HIPAA covered entity, not a business associate of covered entities in most transactions, not a law firm, and not a privacy compliance consultant; references throughout to specific HIPAA provisions, disclosure chain descriptions, retention requirements, and operational standards are illustrative of industry-standard practice rather than authoritative privacy interpretation or business relationship. Always consult qualified legal, privacy, tax, financial, and healthcare compliance advisors familiar with your specific situation before making any allocation, disclosure, or compliance decision.